Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.

Stephan MiehlkeChristoph SchlagAlfredo J LucendoLuc BiedermannCecilio Santander VaqueroChristoph SchmoeckerJamal HayatPetr HruzConstanza Ciriza de Los RiosAlbert Jan BredenoordMichael ViethAlain SchoepferStephen AttwoodRalph MuellerSarah BurrackRoland GreinwaldAlex Straumannnull null

Published in: United European gastroenterology journal (2022)

In this large prospective trial, a 6-week open-label treatment with BOT 1 mg BID was highly effective and safe in achieving clinico-histological remission of active EoE and confirmed the results of the placebo-controlled EOS-1 trial.

Keyphrases

phase iii
open label
phase ii
study protocol
placebo controlled
clinical trial
double blind
randomized controlled trial
phase ii study
disease activity
ulcerative colitis
rheumatoid arthritis
systemic lupus erythematosus
locally advanced
smoking cessation
combination therapy